Posted by Michael Wonder on 12 Oct 2021
NICE guidance on inclisiran should be reconsidered
12 October 2021 - Recommendation is premature without data on cardiovascular outcomes.
NICE recently published draft guidance recommending inclisiran, a new cholesterol lowering drug, for selected patient groups.
The director of the Centre for Health Technology Evaluation at NICE, Meindert Boysen, stated: “Inclisiran represents a potential game-changer in preventing thousands of people from dying prematurely from heart attacks and strokes.
